Morgan Stanley strategists highlighted companies that look likely to impress with earnings including Chewy, Eaton, Nvidia, ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Aging America may revive healthcare stocks after a rough year — discover why long-term trends point to a powerful rebound.

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Dr Suzanne Wylie has outlined the three Mounjaro side effects that could be a cause for concern around hair loss ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

Viking Therapeutics stock fell Thursday after it reported a widening quarterly earnings loss—but that doesn’t mean it won’t eventually pose a threat to Eli Lilly and Novo Nordisk in the weight-loss ...

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also ...